Eltrombopag in children with severe aplastic anemia

Area of Science:

• Pediatric Hematology
• Aplastic Anemia Research
• Immunosuppressive Therapy

Background:

• Standard therapy for pediatric severe aplastic anemia (SAA) lacking HLA-identical siblings includes horse antithymocyte globulin and cyclosporine.
• Eltrombopag, a thrombopoietin receptor agonist, is approved for SAA patients aged 2 years and older, but pediatric data are limited.

Purpose of the Study:

• To evaluate the safety and efficacy of eltrombopag combined with standard immunosuppressive therapy (IST-Epag) versus standard IST alone (IST-Std) in pediatric SAA patients.
• To assess objective response (OR) and complete response (CR) rates at 6 and 12 months post-treatment.

Main Methods:

• Retrospective study of pediatric SAA patients (≤18 years) diagnosed between 2000-2018.
• Patients received either IST-Std or IST-Epag (upfront or after failed IST).
• Primary outcome: OR (partial and complete response) at 6 and 12 months.

Main Results:

• IST-Epag showed high OR (100% at 12 months) and CR (29% at 12 months) in upfront treatment, comparable to IST-Std (OR 100%, CR 58% at 12 months).
• Two patients with prior IST failure did not respond to eltrombopag.
• No significant differences in infections; one patient had transient transaminitis. No changes in PNH clone size or cytogenetics were observed.

Conclusions:

• Addition of eltrombopag to standard IST is well-tolerated and yields satisfactory hematological response in pediatric SAA.
• Further research with larger cohorts and longer follow-up is needed to confirm response durability.